Complement-targeted therapeutics: An emerging field enabled by academic drug discovery.

Area of Science:

• Immunology
• Pharmacology
• Drug Discovery

Background:

• The complement system's role in disease has long been known, but it was not traditionally viewed as a drug target.
• Factors like safety concerns, target complexity, and high protein concentrations hindered early therapeutic development.
• Recent advancements have shifted the complement system into the spotlight for pharmaceutical research.

Purpose of the Study:

• To document the remarkable development of complement inhibitors in therapeutics.
• To highlight the transition of the complement system from a neglected target to a platform technology.
• To provide insights into the future trajectory of complement-targeted therapies.

Main Methods:

• Review and documentation of the development of complement inhibitors.
• Analysis of factors contributing to the delayed and subsequent rapid advancement of complement therapeutics.
• Case examples illustrating the progress in the field.

Main Results:

• A significant increase in complement inhibitors in late-stage clinical trials and approved therapies.
• The emergence of complement modulation as a versatile platform technology for diverse disorders.
• Successful navigation of previous challenges in complement-targeted drug discovery.

Conclusions:

• Complement inhibitors represent a rapidly evolving therapeutic area with broad potential.
• Academic and clinical research innovation has been crucial in advancing complement therapeutics.
• The field is poised for continued growth and significant impact across various diseases.